Table 4.

Neurologic events and CRS leading to treatment interruption in long-term survivors

Patient No.*	Blinatumomab dose (μg/m2/d)	Cycle	Adverse event, CTCAE grade	Blinatumomab dose at restart of treatment (μg/m2/d)	Prophylaxis	Response, RFS, OS	Alive/In remission
5	15	1	Convulsion, grade 2	5	Clobazam	CRh,	Yes/No (relapse)
						RFS 17.5 mo,
						OS 38.6 mo
20	30	2	Encephalopathy, grade 3	5	No	CR,	Yes/Yes
						RFS 34.1 mo,
						OS 36.9 mo
10	5	1	CRS, grade 4	5	Prephase dexamethasone†	CRh,	Yes/Yes
						RFS 22.4 mo,
						OS 30.0 mo‡

Long-term survivors were defined as patients with an OS ≥30 mo.

CTCAE, Common Terminology Criteria for Adverse Events (Version 4.0).

^*Patient No. refers to patients listed in supplemental Table 1.

^†Up to 24 mg/d dexamethasone for up to 5 d and/or 200 mg/m²/d cyclophosphamide for up to 4 d before blinatumomab infusion.

^‡Patient first achieved remission on study day 99 and had to restart cycle 1 after interruptions.